论文部分内容阅读
目的观察曲美他嗪治疗缺血性心肌病的临床疗效。方法选择2006年1月至2010年1月我科收治的缺血性心肌病患者共76例,随机分为两组:对照组36例,观察组40例。用6min步行试验(6MWT)、超声心动图(UCG)评价曲美他嗪辅助治疗缺血性心肌病的疗效。结果观察组治疗前后自身比较:除左室射血分数(LVEF)以外,6min步行距离(6MWD)、左室收缩末期容积指数(LVES-VI)、左室舒张末期容积指数(LVEDVI)差异均有统计学意义;治疗后的组间比较示曲美他嗪进一步提高缺血性心肌病患者的6MWD,降低LVESVI,无不良反应出现。结论曲美他嗪可减轻心肌缺血,减少耗氧量,对心脏有保护作用,可作为治疗缺血性心肌病的常规联用药物。
Objective To observe the clinical efficacy of trimetazidine in the treatment of ischemic cardiomyopathy. Methods 76 patients with ischemic cardiomyopathy treated in our department from January 2006 to January 2010 were randomly divided into two groups: control group (36 cases) and observation group (40 cases). 6-minute walk test (6MWT) and echocardiography (UCG) were used to evaluate the efficacy of trimetazidine in the treatment of ischemic cardiomyopathy. Results Before and after treatment, there were significant differences in 6MWD, LVES-VI and LVEDVI before and after treatment in all groups except for left ventricular ejection fraction (LVEF) Statistical significance; After treatment between the groups showed trimetazidine to further improve 6MWD in patients with ischemic cardiomyopathy, reduce LVESVI, no adverse reactions. Conclusion Trimetazidine can reduce myocardial ischemia, reduce oxygen consumption, has a protective effect on the heart, can be used as a conventional combination therapy for ischemic cardiomyopathy.